Loading...
Market
What will be Tryngolza's market share by December 31, 2025?
2
Resolution / Starting Odds
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
Industry reports and market analysis studies
Story
Ionis Pharmaceuticals Secures FDA Approval for Tryngolza, Its First Wholly-Owned Drug for Familial Chylomicronemia Syndrome, Lowers Triglycerides
Dec 19, 2024, 10:25 PM
Ionis Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for its drug Tryngolza, designed to treat familial chylomicronemia syndrome, a rare genetic disorder that affects the body's ability to break down fats. This approval marks a significant milestone for Ionis, as it is the company's first wholly-owned drug. The therapy works by lowering triglyceride levels in patients suffering from this condition, which can lead to severe health complications. The FDA's decision was confirmed through various sources, highlighting the importance of this approval for both the company and patients in need of effective treatment options.
View original story
Similar markets
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%